Sirnaomics Bets On RNAi In China With First IND Approval
Alan Y Lu, Executive VP of RNAi developer Sirnaomics, talks to Scrip’s Brian Yang about the US-China hybrid's plan to develop anti-fibrosis therapies in both markets.
Alan Y Lu, Executive VP of RNAi developer Sirnaomics, talks to Scrip’s Brian Yang about the US-China hybrid's plan to develop anti-fibrosis therapies in both markets.